ArticleAnalytical chemistry2026
Point-of-Care Radiation Biodosimetry via a Body-Heated Reverse Transcription-Recombinase Polymerase Amplification Coupled to a Paper-Based Vertical Flow Immunoassay.
Article in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Rapid biodosimetry at the point of care is critical for efficient triage and clinical management during mass-casualty radiological events. Here, we introduce a power-free biodosimetry platform integrating one-step reverse transcription recombinase polymerase amplification (RT-RPA) with vertical flow immunoassay (VFI) for the multiplex detection of two radiation-responsive transcripts (CDKN1A and DDB2) and housekeeping gene (MRPS5) from fingerstick blood. One-step RT-RPA showed optimal efficiency at 36 °C for 20 min, comparable to two-step RT-RPA and standard PCR. This temperature could be provided by the human body, where the axilla delivered a stable heat source (36.2 °C) with minimal interindividual variability across a range of environmental conditions (from 4 to 42 °C), supporting amplification comparable to thermocycler-based reactions. Amplified products were detected using a capillary-driven VFI platform. The assay demonstrated strong specificity, uniform signal distribution, and reproducibility with intra- and interassay coefficient of variation below 10% and 15%, respectively, across all three transcripts. When applied to ex vivo X-ray irradiated blood samples (1 and 2 Gy), a dose-dependent increase in CDKN1A and DDB2 signals was observed. Receiver operating characteristic analysis demonstrated that discrimination between sham- and 1 Gy-irradiated was not significant, whereas the assay distinguished sham- from 2 Gy-irradiated with area under the curve values of 0.82 (95% CI = [0.66-0.98]; p = 0.0052) and 0.89 (95% CI = [0.76-1.00]; p = 0.0006) for CDKN1A and DDB2, yielding sensitivity/specificity of 84.62%/69.23% and 92.31%/84.62%, respectively. These findings supported the feasibility of the body-heat one-step RT-RPA VFI as a rapid, equipment-free, field-deployable triage tool for large-scale radiation biodosimetry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.